Skip to main content
CGEN logo

Compugen Ltd. (CGEN) Stock: Price, Forecast & Analyst Target

Compugen Ltd. (CGEN) — MoonshotScore 69/100 (Strong band), calculated Nov 18, 2026. Price $1.88 (-4.08%), as of the Nov 19, 2026 trading session; market cap $178M.

Educational signal · not a buy or sell recommendation · How to read this

$1.88 −$0.08 (-4.08%) Market Cap $178M

Compugen Ltd. · CGEN · NASDAQ

Compugen Ltd. is a clinical-stage biotechnology company focused on the development of immuno-oncology therapies. With a robust pipeline of therapeutic candidates, the company aims to innovate treatments for solid tumors and advanced malignancies.

Price as of Nov 19, 2026

Key Statistics

69 of 100

MoonshotScore v2 · Compugen (CGEN)

Strong
Business Quality Elite (97)
Financial Safety Okay (57)
Valuation Cheap (81)
Growth Durability Compounding (99)
Momentum Rising (61)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Elite quality and elite growth, at a cheap price, though the balance sheet is only decent. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Rising.

  • EPS beat 4 of the last 8 reports
  • Altman Z 4.86 · Piotroski F 5
  • ROE 57.2% · ROA 17.2% · current ratio 4.90

Helping: business quality, an attractive price, durable growth

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for CGEN (52 recorded, newest six shown)
RecordedScoreBand
68Strong
69Strong
69Strong
69Strong
69Strong
69Strong

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.88
Change on the day-4.08%
52-week range$1.43 – $3.24
Market capitalisation$178M—
Price / earnings (trailing)5.20
Shares traded on the day262.6K

Price & events

Other perspectives

Council score for Compugen (CGEN): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Neutral
Valuation Strong
Growth Durability Strong
Momentum Moderate

Legends Council

6 lenses, 6 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 20, 2026

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Strong
Margin of Safety Undervalued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Strong
ROE Strong
Gross Margin Strong

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Compugen (CGEN), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Compugen Ltd. (CGEN) is listed on NASDAQ. It employs 75 people and is led by Eran Ophir. The market values it at $178M.

2 · Latest results

What do the latest results show for Compugen (CGEN)?

Short answer · as of

Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$2M-$7M-$0.07 (diluted)
Q4 FY2025$67M$57M$0.60 (diluted)
Q1 FY2026$2M-$8M-$0.08 (diluted)
Q2 FY2026$3M-$7M-$0.07 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Compugen (CGEN)?

Short answer

The MoonshotScore pillars rate business quality, an attractive price, durable growth as strengths. The distress and quality screens read Altman Z 4.86 · Piotroski F 5. Trailing ratios: ROE 57.2% · ROA 17.2% · current ratio 4.90.

4 · What to check next?

What should you watch next at Compugen (CGEN)?

Short answer · as of

Current published price targets run low $5.00 · high $5.00 · consensus $5.00 · median $5.00 against a quoted price of $1.88 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Compugen compare with its peers?

Short answer

Compugen's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.06 Nov 19, 2026$258M90 5-pillar Nov 18, 2026
Bristol-Myers Squibb Company (BMY) Named competitor$58.34 Nov 19, 2026$119B85 5-pillar Nov 18, 2026
AstraZeneca PLC (AZN) Named competitor$178.76 Nov 18, 2026$277B85 5-pillar Nov 18, 2026
Novartis AG (NVS) Named competitor$155.21 Nov 18, 2026$293B82 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen (CGEN) — this page$1.88$178M69
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.14 Nov 19, 2026$796M63 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$5.00 – $5.00
Consensus target
$5.00
Median target
$5.00

Consensus record · Captured .

Measured against a quoted price of $1.88 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Jul 29, 2026

Transactions
24
Identified insiders
12
Purchases
0
Sales
1
Other transactions
23

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held CGEN in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
ARK InvestCathie WoodQ3 20260.01%$2.11MAdded +12.9% shares

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Compugen (CGEN)?

Read these with our analysis →

Compugen Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the CGEN research dossier (written Jun 13, 2026 by gpt-4o-mini); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for CGEN?

CGEN carries the MoonshotScore stated above — the Strong band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Compugen Ltd. is a clinical-stage biotechnology company focused on the development of immuno-oncology therapies.

Is CGEN a good stock to buy?

Stock Expert AI does not rate CGEN buy, sell or hold. Compugen Ltd. carries a MoonshotScore, in the Strong band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the CGEN stock price today?

The last price recorded for Compugen Ltd. (CGEN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the CGEN price target?

The analyst consensus price target for Compugen Ltd. (CGEN), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for CGEN?

Compugen Ltd. faces several risks, including dependence on the successful outcomes of its clinical trials, which are critical for advancing its therapeutic candidates.

What are the key factors to evaluate for CGEN?

Compugen Ltd. (CGEN) holds a MoonshotScore in the moderate range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Global Market Expansion: With its headquarters in Israel and operations in the U.S. and Europe, Compugen is well-positioned to tap into international markets. Not financial advice.

How frequently does CGEN data refresh on this page?

CGEN's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven CGEN's recent stock price performance?

Compugen Ltd. (CGEN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline with multiple Phase I clinical studies. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider CGEN overvalued or undervalued right now?

The trailing P/E of Compugen Ltd. (CGEN) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 18 figures on this page — 10 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.